ARTL - Artelo Biosciences, Inc.

Company Profile

Artelo Biosciences, Inc. is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company is headquartered in La Jolla, California and currently employs 1 full-time employees. The firm is focused on licensing, developing and commercializing treatments intended to modulate the endocannabinoid system (ECS). The company develops and commercializes ethical pharmaceutical products that provide physicians access to the therapeutic potential of cannabinoid therapeutics and other modulators of the ECS for their patients. Its pipeline includes ART12.11, ART26.12 and ART27.13. The firm is developing ART12.11 for targeting the development in Inflammatory Bowel Disease (IBD), stroke and rare/orphan diseases. ART26.12 is its endocannabinoid transport protein (FABP5) inhibitor for treatment of breast cancer, prostate cancer, and neuropathic and nociceptive pain. ART27.13 is being developed for cancer. The firm also intends to develop a formulation suitable for treatment of anorexia/weight loss associated with cancer (cachexia).